Loading…
Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents
A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they gene...
Saved in:
Published in: | Bioorganic & medicinal chemistry 1998-03, Vol.6 (3), p.301-314 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253 |
---|---|
cites | cdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253 |
container_end_page | 314 |
container_issue | 3 |
container_start_page | 301 |
container_title | Bioorganic & medicinal chemistry |
container_volume | 6 |
creator | Kanaoka, Yoshitomo Ikeuchi, Yoshihiro Kawamoto, Tetsuji Bessho, Kiyoshi Akimoto, Naoshige Mikata, Yuji Nishida, Mamiko Yano, Shigenobu Sasaki, Takuma Yoneda, Fumio |
description | A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds. |
doi_str_mv | 10.1016/S0968-0896(97)10036-0 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79826618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0968089697100360</els_id><sourcerecordid>79826618</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</originalsourceid><addsrcrecordid>eNqFUctu1DAUtRCoTAufUMkr1C4CfiR2vEJVoYBUwaKwtm7sm9YoiQfbiRg-ga8m0xl1y-ouzkv3HELOOXvLGVfv7phRbcVaoy6MvuSMSVWxZ2TDa1VXUhr-nGyeKC_Jac4_GWOiNvyEnJhGtaKtN-Tv3W4qD5hDpjB5igsMM5QQJxp7OoWSIm0qj_AH-gGWMFXbXUpxQAepi79hDB4v8iV92HUpeDrukXnA1SzTKS440A9fr2iBdI8FPe1CTOhnV8KCa14JZR5jonCPU8mvyIsehoyvj_eM_Lj5-P36c3X77dOX66vbygmm6wqUVNLVThutHPa1gU6gV8J3vkHBte6MRGmkbrQTqMAr6IzmElQtmRCNPCNvDr7bFH_NmIsdQ3Y4DDBhnLPVphVK8XYlNgeiSzHnhL3dpjBC2lnO7H4D-7iB3RdsjbaPG1i26s6PAXM3on9SHUtf8fcHHNcvl4DJZhdwcuhDQlesj-E_Cf8Aoi6ZUA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79826618</pqid></control><display><type>article</type><title>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Kanaoka, Yoshitomo ; Ikeuchi, Yoshihiro ; Kawamoto, Tetsuji ; Bessho, Kiyoshi ; Akimoto, Naoshige ; Mikata, Yuji ; Nishida, Mamiko ; Yano, Shigenobu ; Sasaki, Takuma ; Yoneda, Fumio</creator><creatorcontrib>Kanaoka, Yoshitomo ; Ikeuchi, Yoshihiro ; Kawamoto, Tetsuji ; Bessho, Kiyoshi ; Akimoto, Naoshige ; Mikata, Yuji ; Nishida, Mamiko ; Yano, Shigenobu ; Sasaki, Takuma ; Yoneda, Fumio</creatorcontrib><description>A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.</description><identifier>ISSN: 0968-0896</identifier><identifier>EISSN: 1464-3391</identifier><identifier>DOI: 10.1016/S0968-0896(97)10036-0</identifier><identifier>PMID: 9568284</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Antineoplastic Agents - chemical synthesis ; Antineoplastic Agents - pharmacology ; DNA - drug effects ; DNA - metabolism ; DNA Damage ; Drug Screening Assays, Antitumor ; Flavins - chemical synthesis ; Flavins - pharmacology ; Humans ; KB Cells ; Leukemia L1210 - drug therapy ; Mice ; Oxidation-Reduction ; Pyrroles - chemical synthesis ; Pyrroles - pharmacology ; Structure-Activity Relationship</subject><ispartof>Bioorganic & medicinal chemistry, 1998-03, Vol.6 (3), p.301-314</ispartof><rights>1997 Elsevier Science Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</citedby><cites>FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9568284$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kanaoka, Yoshitomo</creatorcontrib><creatorcontrib>Ikeuchi, Yoshihiro</creatorcontrib><creatorcontrib>Kawamoto, Tetsuji</creatorcontrib><creatorcontrib>Bessho, Kiyoshi</creatorcontrib><creatorcontrib>Akimoto, Naoshige</creatorcontrib><creatorcontrib>Mikata, Yuji</creatorcontrib><creatorcontrib>Nishida, Mamiko</creatorcontrib><creatorcontrib>Yano, Shigenobu</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Yoneda, Fumio</creatorcontrib><title>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</title><title>Bioorganic & medicinal chemistry</title><addtitle>Bioorg Med Chem</addtitle><description>A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemical synthesis</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>DNA - drug effects</subject><subject>DNA - metabolism</subject><subject>DNA Damage</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Flavins - chemical synthesis</subject><subject>Flavins - pharmacology</subject><subject>Humans</subject><subject>KB Cells</subject><subject>Leukemia L1210 - drug therapy</subject><subject>Mice</subject><subject>Oxidation-Reduction</subject><subject>Pyrroles - chemical synthesis</subject><subject>Pyrroles - pharmacology</subject><subject>Structure-Activity Relationship</subject><issn>0968-0896</issn><issn>1464-3391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFUctu1DAUtRCoTAufUMkr1C4CfiR2vEJVoYBUwaKwtm7sm9YoiQfbiRg-ga8m0xl1y-ouzkv3HELOOXvLGVfv7phRbcVaoy6MvuSMSVWxZ2TDa1VXUhr-nGyeKC_Jac4_GWOiNvyEnJhGtaKtN-Tv3W4qD5hDpjB5igsMM5QQJxp7OoWSIm0qj_AH-gGWMFXbXUpxQAepi79hDB4v8iV92HUpeDrukXnA1SzTKS440A9fr2iBdI8FPe1CTOhnV8KCa14JZR5jonCPU8mvyIsehoyvj_eM_Lj5-P36c3X77dOX66vbygmm6wqUVNLVThutHPa1gU6gV8J3vkHBte6MRGmkbrQTqMAr6IzmElQtmRCNPCNvDr7bFH_NmIsdQ3Y4DDBhnLPVphVK8XYlNgeiSzHnhL3dpjBC2lnO7H4D-7iB3RdsjbaPG1i26s6PAXM3on9SHUtf8fcHHNcvl4DJZhdwcuhDQlesj-E_Cf8Aoi6ZUA</recordid><startdate>199803</startdate><enddate>199803</enddate><creator>Kanaoka, Yoshitomo</creator><creator>Ikeuchi, Yoshihiro</creator><creator>Kawamoto, Tetsuji</creator><creator>Bessho, Kiyoshi</creator><creator>Akimoto, Naoshige</creator><creator>Mikata, Yuji</creator><creator>Nishida, Mamiko</creator><creator>Yano, Shigenobu</creator><creator>Sasaki, Takuma</creator><creator>Yoneda, Fumio</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199803</creationdate><title>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</title><author>Kanaoka, Yoshitomo ; Ikeuchi, Yoshihiro ; Kawamoto, Tetsuji ; Bessho, Kiyoshi ; Akimoto, Naoshige ; Mikata, Yuji ; Nishida, Mamiko ; Yano, Shigenobu ; Sasaki, Takuma ; Yoneda, Fumio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemical synthesis</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>DNA - drug effects</topic><topic>DNA - metabolism</topic><topic>DNA Damage</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Flavins - chemical synthesis</topic><topic>Flavins - pharmacology</topic><topic>Humans</topic><topic>KB Cells</topic><topic>Leukemia L1210 - drug therapy</topic><topic>Mice</topic><topic>Oxidation-Reduction</topic><topic>Pyrroles - chemical synthesis</topic><topic>Pyrroles - pharmacology</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kanaoka, Yoshitomo</creatorcontrib><creatorcontrib>Ikeuchi, Yoshihiro</creatorcontrib><creatorcontrib>Kawamoto, Tetsuji</creatorcontrib><creatorcontrib>Bessho, Kiyoshi</creatorcontrib><creatorcontrib>Akimoto, Naoshige</creatorcontrib><creatorcontrib>Mikata, Yuji</creatorcontrib><creatorcontrib>Nishida, Mamiko</creatorcontrib><creatorcontrib>Yano, Shigenobu</creatorcontrib><creatorcontrib>Sasaki, Takuma</creatorcontrib><creatorcontrib>Yoneda, Fumio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic & medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kanaoka, Yoshitomo</au><au>Ikeuchi, Yoshihiro</au><au>Kawamoto, Tetsuji</au><au>Bessho, Kiyoshi</au><au>Akimoto, Naoshige</au><au>Mikata, Yuji</au><au>Nishida, Mamiko</au><au>Yano, Shigenobu</au><au>Sasaki, Takuma</au><au>Yoneda, Fumio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents</atitle><jtitle>Bioorganic & medicinal chemistry</jtitle><addtitle>Bioorg Med Chem</addtitle><date>1998-03</date><risdate>1998</risdate><volume>6</volume><issue>3</issue><spage>301</spage><epage>314</epage><pages>301-314</pages><issn>0968-0896</issn><eissn>1464-3391</eissn><abstract>A series of 6-nitro-5-deazaflavins bearing at N(3) or N(10) position the pyrrolecarboxamide(s) group as DNA minor groove binder has been synthesized. These hybrid molecules show similar redox properties to those of 6-nitro-5-deazaflavins with no pyrrolecarboxamide(s) group, suggesting that they generate stable one- and two-electron reduction product(s). Electrolytic reductions of the hybrid molecules were carried out at a controlled potential under anaerobic conditions in the presence of plasmid pBR322 DNA. Significant conversions of the supercoiled circular pBR322 DNA (form I) to the open circular DNA (form II) have been found by treatment with the reductively activated 6-nitro-5-deazaflavin derivatives. Their DNA damaging effects have been found to be enhanced as the number of pyrrolecarboxamide group as the DNA binder increases. Antitumor activities of the hybrid molecules towards KB and L1210 cells were evaluated in vitro. It has been found that the antitumor effects of the compounds on KB cells slightly change and those on L1210 cells decrease as the number of the pyrrolecarboxamide group increases. These results reveal that the combination of 6-nitro-5-deazaflavin molecule with the pyrrolecarboxamide(s) group increase the DNA binding properties of the compounds, giving rise to promoted DNA damaging effects, and also suggest that the combination would affect the capacity of the compounds to act as the substrate for intracellular reductases and/or the cellular uptake of the compounds.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>9568284</pmid><doi>10.1016/S0968-0896(97)10036-0</doi><tpages>14</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0968-0896 |
ispartof | Bioorganic & medicinal chemistry, 1998-03, Vol.6 (3), p.301-314 |
issn | 0968-0896 1464-3391 |
language | eng |
recordid | cdi_proquest_miscellaneous_79826618 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Animals Antineoplastic Agents - chemical synthesis Antineoplastic Agents - pharmacology DNA - drug effects DNA - metabolism DNA Damage Drug Screening Assays, Antitumor Flavins - chemical synthesis Flavins - pharmacology Humans KB Cells Leukemia L1210 - drug therapy Mice Oxidation-Reduction Pyrroles - chemical synthesis Pyrroles - pharmacology Structure-Activity Relationship |
title | Synthesis and evaluation of nitro 5-deazaflavin-pyrrolecarboxamide(s) hybrid molecules as novel DNA targeted bioreductive antitumor agents |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A21%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20and%20evaluation%20of%20nitro%205-deazaflavin-pyrrolecarboxamide(s)%20hybrid%20molecules%20as%20novel%20DNA%20targeted%20bioreductive%20antitumor%20agents&rft.jtitle=Bioorganic%20&%20medicinal%20chemistry&rft.au=Kanaoka,%20Yoshitomo&rft.date=1998-03&rft.volume=6&rft.issue=3&rft.spage=301&rft.epage=314&rft.pages=301-314&rft.issn=0968-0896&rft.eissn=1464-3391&rft_id=info:doi/10.1016/S0968-0896(97)10036-0&rft_dat=%3Cproquest_cross%3E79826618%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2074-a6363c4c7976cef49ab2ed62dbd5e2177b93e393757c2e6ad6ab9713a64302253%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79826618&rft_id=info:pmid/9568284&rfr_iscdi=true |